← All Posts
Pfizer Inc.
April 23, 2026
•
Author: Phil Ratcliff
| Item |
Proposal |
Vote |
| 1 |
Election of Directors |
|
| 1.01 |
Ronald E. Blaylock |
✓ For(3160.34)
|
| 1.02 |
Albert Bourla |
✗ Against(3160.34)
|
| 1.03 |
Mortimer J. Buckley |
✓ For(3160.34)
|
| 1.04 |
Susan Desmond-Hellmann |
✓ For(3160.34)
|
| 1.05 |
Joseph J. Echevarria |
✓ For(3160.34)
|
| 1.06 |
Scott Gottlieb |
✓ For(3160.34)
|
| 1.07 |
Dan R. Littman |
✓ For(3160.34)
|
| 1.08 |
Shantanu Narayen |
✓ For(3160.34)
|
| 1.09 |
Suzanne Nora Johnson |
✓ For(3160.34)
|
| 1.10 |
James Quincey |
✓ For(3160.34)
|
| 1.11 |
James C. Smith |
✓ For(3160.34)
|
| 1.12 |
Cyrus Taraporevala |
✓ For(3160.34)
|
| 2 |
Ratify the selection of KPMG LLP as our independent registered public accounting firm for 2026 |
✓ For(3160.34)
|
| 3 |
Approval of the Pfizer Inc. 2019 Stock Plan, as amended April 2026 |
✓ For(3160.34)
|
| 4 |
2026 advisory approval of executive compensation |
✓ For(3160.34)
|
| 5 |
Adopt an Independent Chair Policy |
✓ For(3160.34)
|
This article was written for information purposes only and its content should not be
construed by any consumer and/or prospective client as rebel Financial's solicitation
to affect, or attempt to affect transactions in securities, or the rendering of
personalized investment advice for compensation. No client or prospective client should
assume that any such discussion serves as the receipt of, or a substitute for,
personalized advice from rebel Financial, or from any other investment professional.
See our disclosures page for more information.
rebel Financial